Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.99
USD
|
+3.37%
|
|
-2.92%
|
+30.82%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
993.3
|
684.4
|
434.2
|
274.8
|
158.1
|
208.7
|
-
|
-
|
Enterprise Value (EV)
1 |
724.1
|
684.4
|
434.2
|
274.8
|
158.1
|
208.7
|
208.7
|
-2,366
|
P/E ratio
|
-8.08
x
|
-6.87
x
|
-2.88
x
|
-1.61
x
|
-3.28
x
|
-5.99
x
|
-14.2
x
|
1.01
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
15.1
x
|
13.8
x
|
5.36
x
|
1.92
x
|
3.03
x
|
2.05
x
|
0.6
x
|
EV / Revenue
|
-
|
15.1
x
|
13.8
x
|
5.36
x
|
1.92
x
|
3.03
x
|
2.05
x
|
0.6
x
|
EV / EBITDA
|
-7.72
x
|
-7.14
x
|
-3.06
x
|
-2.03
x
|
-4.05
x
|
-6.23
x
|
-10.4
x
|
0.44
x
|
EV / FCF
|
-9.71
x
|
-8.17
x
|
-3.29
x
|
-
|
-4.12
x
|
20.9
x
|
9.94
x
|
0.22
x
|
FCF Yield
|
-10.3%
|
-12.2%
|
-30.4%
|
-
|
-24.2%
|
4.79%
|
10.1%
|
462%
|
Price to Book
|
3.89
x
|
3.87
x
|
3.03
x
|
-
|
4.46
x
|
4.53
x
|
2.72
x
|
0.07
x
|
Nbr of stocks (in thousands)
|
37,582
|
38,046
|
42,522
|
50,612
|
51,844
|
52,305
|
-
|
-
|
Reference price
2 |
26.43
|
17.99
|
10.21
|
5.430
|
3.050
|
3.990
|
3.990
|
3.990
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/23/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
45.28
|
31.48
|
51.3
|
82.51
|
68.9
|
101.7
|
347.7
|
EBITDA
1 |
-128.7
|
-95.89
|
-142
|
-135.6
|
-39.01
|
-33.5
|
-20
|
477
|
EBIT
1 |
-129
|
-96.48
|
-142.5
|
-136.2
|
-39.53
|
-34.23
|
-18.72
|
187.7
|
Operating Margin
|
-
|
-213.04%
|
-452.59%
|
-265.45%
|
-47.91%
|
-49.68%
|
-18.41%
|
53.99%
|
Earnings before Tax (EBT)
1 |
-122.4
|
-97.84
|
-147.4
|
-145.9
|
-44.85
|
-37.63
|
-20.81
|
186.6
|
Net income
1 |
-122.4
|
-99.25
|
-148.4
|
-147.6
|
-47.97
|
-37.56
|
-20.78
|
186.5
|
Net margin
|
-
|
-219.18%
|
-471.32%
|
-287.63%
|
-58.13%
|
-54.52%
|
-20.43%
|
53.66%
|
EPS
2 |
-3.270
|
-2.620
|
-3.540
|
-3.380
|
-0.9300
|
-0.6665
|
-0.2803
|
3.934
|
Free Cash Flow
1 |
-102.3
|
-83.74
|
-132.1
|
-
|
-38.34
|
10
|
21
|
965
|
FCF margin
|
-
|
-184.92%
|
-419.71%
|
-
|
-46.46%
|
14.51%
|
20.65%
|
277.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
202.33%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
517.31%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/23/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
4.858
|
5.796
|
6.902
|
10.57
|
23.58
|
10.25
|
12.95
|
42.39
|
12.3
|
14.87
|
15.08
|
16.2
|
17.45
|
20.09
|
24.76
|
EBITDA
1 |
-41.03
|
-37.47
|
-46.67
|
-36.82
|
-21.41
|
-30.75
|
-25.61
|
11.65
|
-16.24
|
-8.805
|
-9
|
-8.5
|
-8
|
-8
|
-2
|
EBIT
1 |
-41.14
|
-37.59
|
-46.78
|
-36.96
|
-21.55
|
-30.89
|
-25.75
|
11.52
|
-16.37
|
-8.929
|
-9.449
|
-8.918
|
-8.822
|
-6.99
|
-4.905
|
Operating Margin
|
-846.93%
|
-648.48%
|
-677.79%
|
-349.59%
|
-91.4%
|
-301.34%
|
-198.87%
|
27.17%
|
-133.07%
|
-60.03%
|
-62.68%
|
-55.05%
|
-50.54%
|
-34.8%
|
-19.81%
|
Earnings before Tax (EBT)
1 |
-42.15
|
-39.77
|
-49.19
|
-39.45
|
-24.05
|
-33.17
|
-27.6
|
10.02
|
-17.3
|
-9.976
|
-10.37
|
-9.809
|
-9.588
|
-7.716
|
-5.905
|
Net income
1 |
-42.47
|
-40.02
|
-49.19
|
-39.45
|
-25.27
|
-33.65
|
-27.6
|
8.71
|
-18.2
|
-10.88
|
-10.37
|
-9.809
|
-9.588
|
-7.716
|
-5.905
|
Net margin
|
-874.19%
|
-690.48%
|
-712.72%
|
-373.08%
|
-107.19%
|
-328.28%
|
-213.15%
|
20.55%
|
-148%
|
-73.14%
|
-68.8%
|
-60.55%
|
-54.93%
|
-38.41%
|
-23.85%
|
EPS
2 |
-1.000
|
-0.9400
|
-1.150
|
-0.9200
|
-0.5900
|
-0.7300
|
-0.5300
|
0.1400
|
-0.3500
|
-0.2100
|
-0.1981
|
-0.1874
|
-0.1635
|
-0.1252
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/23/22
|
5/4/22
|
8/3/22
|
11/2/22
|
3/1/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
269
|
-
|
-
|
-
|
-
|
-
|
-
|
2,575
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-102
|
-83.7
|
-132
|
-
|
-38.3
|
10
|
21
|
965
|
ROE (net income / shareholders' equity)
|
-39.9%
|
-45.9%
|
-92.5%
|
-139%
|
-92.1%
|
-88.1%
|
-29.9%
|
69.3%
|
ROA (Net income/ Total Assets)
|
-37.3%
|
-38.7%
|
-61.5%
|
-66.8%
|
-31%
|
-41.5%
|
-25.2%
|
68.4%
|
Assets
1 |
328.1
|
256.7
|
241.3
|
221
|
154.8
|
90.52
|
82.6
|
272.9
|
Book Value Per Share
2 |
6.790
|
4.650
|
3.370
|
-
|
0.6800
|
0.8800
|
1.460
|
53.60
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.72
|
-
|
-
|
-
|
-
|
-
|
0.25
|
2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
0.25%
|
0.58%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/23/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
3.99
USD Average target price
8.5
USD Spread / Average Target +113.03% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.82% | 209M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|